Current Report Filing (8-k)
17 February 2021 - 8:44AM
Edgar (US Regulatory)
0001566044
false
0001566044
2021-02-16
2021-02-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 16, 2021
VYNE Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-38356
|
|
45-3757789
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
520 U.S. Highway 22, Suite 204
Bridgewater, New Jersey 08807
(Address of principal executive offices, including Zip Code)
(800) 775-7936
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
|
VYNE
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On February 16, 2021, VYNE Therapeutics Inc. (the “Company”)
completed its previously announced reverse stock split. As a result of the reverse stock split, every four shares of issued and
outstanding common stock was automatically combined into one issued and outstanding share of common stock, without any change in
the par value per share. No fractional shares were issued as a result of the reverse stock split. In lieu thereof, the Company’s
transfer agent will aggregate all fractional shares and sell them as soon as practicable at the then-prevailing prices on the open
market. After the transfer agent’s completion of such sale, stockholders who would have been entitled to a fractional share
as a result of the reverse stock split will instead receive a cash payment from the transfer agent in an amount equal to their
respective pro rata share of the total proceeds of that sale. If stockholders have any questions regarding fractional shares, they
should contact the transfer agent, American Stock Transfer & Trust, at 877-248-6417 (toll free).
Following the reverse stock split, there are now
51,326,891 shares of common stock issued and outstanding.
The information being furnished
pursuant to this “Item 7.01 Regulation FD Disclosure” shall not be deemed to be “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act
of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VYNE Therapeutics Inc.
|
|
|
|
|
/s/ Mutya Harsch
|
|
By:
|
Mutya Harsch
|
|
Chief Legal Officer and General Counsel
|
Date: February 16, 2021
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From Apr 2024 to May 2024
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From May 2023 to May 2024